FFA
EDIT icon

Fairfield Financial Advisors’s Editas Medicine EDIT Stock Holding History

Fairfield Financial Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-105
Closed -$490 – 292
2024
Q2 		$490 Buy
+105
New +$592 ﹤0.01% 279
2023
Q4 		$8.56K Buy
845
+300
+55% +$2.63K ﹤0.01% 249
2023
Q3 		$4.25K Hold
545
– – ﹤0.01% 261
2023
Q2 		$4.49K Hold
545
– – ﹤0.01% 275
2023
Q1 		$3.83K Hold
545
– – ﹤0.01% 279
2022
Q4 		$4.83K Hold
545
– – ﹤0.01% 253
2022
Q3 		$6.67K Hold
545
– – ﹤0.01% 247
2022
Q2 		$6.45K Hold
545
– – ﹤0.01% 233
2022
Q1 		$10.4K Buy
+545
New +$10.1K ﹤0.01% 219

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fairfield Financial Advisors's EDIT Position: Q3 2024 in Review

Fairfield Financial Advisors sold out of Editas Medicine (EDIT) in Q3 2024, closing a stake of 105 shares — an estimated $490 sold.

Fairfield Financial Advisors first reported a position in EDIT in Q1 2022 and held it in 9 quarters. The position peaked at $10.4K in Q1 2022. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Fairfield Financial Advisors reported no remaining Editas Medicine position as of Q3 2024 after selling out during the quarter.
  • Fairfield Financial Advisors sold 105 Editas Medicine shares in Q3 2024, an estimated $490.
  • Fairfield Financial Advisors first reported a position in Editas Medicine in Q1 2022 and held it in 9 quarters.
  • Fairfield Financial Advisors's Editas Medicine position peaked at $10.4K in Q1 2022.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Fairfield Financial Advisors's 13F filing for Q3 2024, filed 28 Oct 2024.